Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | February 06, 2019 | February 08, 2019 |
| Kronos Bio, Inc.KRON · Entity 78257 | Director | October 14, 2020 | October 16, 2020 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | March 03, 2021 | March 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date February 06, 2019 · Filed February 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,887,225 |
Ending reported balance
After 2019-02-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-02-06 · Grant · Acquired 7,745 · Balance 2,885,507 F1: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 2 · 2019-02-06 · Grant · Acquired 15,505 · Balance 2,901,012 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 3 · 2019-02-06 · Tax withholding · Disposed 13,787 · Balance 2,887,225 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
Kronos Bio, Inc.
Report date October 14, 2020 · Filed October 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,952,364 |
Last balance in matching sequence
After 2020-10-14 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2020-10-14 · Conversion · Acquired 914,333 · Balance 914,333 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 2 · 2020-10-14 · Conversion · Acquired 756,971 · Balance 1,671,304 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 3 · 2020-10-14 · Conversion · Acquired 205,260 · Balance 1,876,564 F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 4 · 2020-10-14 · Purchase · Acquired 75,800 · Balance 1,952,364 F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Series Seed Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-14 · Conversion · Disposed 866,667 · Balance 0 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-14 · Conversion · Disposed 717,509 · Balance 0 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2022-02-20 | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-14 · Conversion · Disposed Not disclosed · Balance 0 F3: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F3: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering.
Sarepta Therapeutics, Inc.
Report date March 03, 2021 · Filed March 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,913 |
Reported balance
After 2021-03-03 transaction · row 1
1 source rowRow 1 · 2021-03-03 · Grant · Acquired 2,726 · Balance 7,913 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.11 · Expires 2031-03-03 | Direct | 5,518 |
Reported balance
After 2021-03-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-03 · Grant · Acquired 5,518 · Balance 5,518 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2011 Filed Mar 8, 2011 01:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 102,733 | $8.22 | $844,341.98 |
DisclosureSEC source: 0001179110-11-004474 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,189,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2011 Filed Mar 8, 2011 01:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 174,227 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-11-004474 · edgar.xml · derivative · entry 5 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 933,613 Underlying: Common Stock · 174,227 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options had a 5-year vesting schedule. 20% of the options vested on January 30, 2003, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on January 30, 2007. The options expire on January 29, 2012. Read SEC document |
| March 03, 2011 Filed Mar 8, 2011 01:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 174,227 | $40.01 | $6,970,142.78 |
DisclosureSEC source: 0001179110-11-004474 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,015,496 F1 · price: Sale prices reported for the transaction reported here range from $40.00 to $40.03. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 03, 2011 Filed Mar 8, 2011 01:01 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 174,227 | $8.22 | $1,431,936.87 |
DisclosureSEC source: 0001179110-11-004474 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,086,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2011 Filed Jan 25, 2011 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 430,000 | $0.00 Strike: $38.17 | $0.00 |
DisclosureSEC source: 0001179110-11-001268 · edgar.xml · derivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,000 Underlying: Common Stock · 430,000 shares Expires 2021-01-20 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on January 20, 2012 the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested on January 20, 2015. The options expire on January 20, 2021. Read SEC document |
| October 22, 2010 Filed Oct 27, 2010 00:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock option (right to buy) · Derivative | 140,984 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-10-015245 · edgar.xml · derivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,984 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a 5-year vesting schedule. 20% of the options vested on January 18, 2002, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on January 18, 2006. The options expire on January 17, 2011. Read SEC document |
| October 22, 2010 Filed Oct 27, 2010 00:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 140,984 | $3.70 | $521,542.11 |
DisclosureSEC source: 0001179110-10-015245 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,912,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2010 Filed Aug 23, 2010 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock option (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-10-013075 · edgar.xml · derivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,984 Underlying: Common Stock · 125,000 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a 5-year vesting schedule. 20% of the options vested on January 18, 2002, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on January 18, 2006. Read SEC document |
| August 19, 2010 Filed Aug 23, 2010 22:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 125,000 | $3.70 | $462,412.50 |
DisclosureSEC source: 0001179110-10-013075 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,771,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2010 Filed Aug 10, 2010 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock option (right to buy) · Derivative | 12,160 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-10-012455 · edgar.xml · derivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,160 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a 5-year vesting schedule. 20% of the options vested on January 30, 2003, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on January 30, 2007. The options expire on January 29, 2012. Read SEC document |
| August 09, 2010 Filed Aug 10, 2010 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 12,160 | $8.22 | $99,940.61 |
DisclosureSEC source: 0001179110-10-012455 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,646,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Amount of securities beneficially owned following the reported transaction includes 577 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 30, 2010. Read SEC document |
| July 13, 2010 Filed Jul 15, 2010 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-10-011672 · edgar.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,984 Underlying: Common Stock · 100,000 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a 5-year vesting schedule. 20% of the options vested on January 18, 2002, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on January 18, 2006. The options expire on January 17, 2011. Read SEC document |
| July 13, 2010 Filed Jul 15, 2010 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100,000 | $35.15 | $3,515,000.00 |
DisclosureSEC source: 0001179110-10-011672 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,634,042 F1 · price: Sale prices reported for the transaction reported here range from $34.55 to $35.44. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 13, 2010 Filed Jul 15, 2010 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $3.70 | $369,930.00 |
DisclosureSEC source: 0001179110-10-011672 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,734,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2010 Filed Jun 10, 2010 16:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-10-010227 · edgar.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,984 Underlying: Common Stock · 100,000 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options had a 5-year vesting schedule. 20% of the options vested on January 18, 2002, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on January 18, 2006. The options expire on January 17, 2011. Read SEC document |
| June 08, 2010 Filed Jun 10, 2010 16:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 36,700 | $34.24 | $1,256,677.73 |
DisclosureSEC source: 0001179110-10-010227 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,634,042 F2 · price: Sale prices reported for the transaction reported here range from $33.89 to $34.50. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 08, 2010 Filed Jun 10, 2010 16:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 63,300 | $33.41 | $2,114,764.38 |
DisclosureSEC source: 0001179110-10-010227 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,670,742 F1 · price: Sale prices reported for the transaction reported here range from $32.87 to $33.86. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 08, 2010 Filed Jun 10, 2010 16:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $3.70 | $369,930.00 |
DisclosureSEC source: 0001179110-10-010227 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,734,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2010 Filed May 13, 2010 22:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-10-008579 · edgar.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,984 Underlying: Common Stock · 100,000 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options had a 5-year vesting schedule. 20% of the options vested on January 18, 2002, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on January 18, 2006. The options expire on January 17, 2011. Read SEC document |
| May 11, 2010 Filed May 13, 2010 22:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 19,100 | $40.00 | $764,021.01 |
DisclosureSEC source: 0001179110-10-008579 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,634,042 F2 · price: Sale prices reported for the transaction reported here range from $39.80 to $40.20. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 11, 2010 Filed May 13, 2010 22:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 80,900 | $39.52 | $3,196,909.12 |
DisclosureSEC source: 0001179110-10-008579 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,653,142 F1 · price: Sale prices reported for the transaction reported here range from $38.79 to $39.78. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 11, 2010 Filed May 13, 2010 22:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $3.70 | $369,930.00 |
DisclosureSEC source: 0001179110-10-008579 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,734,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2010 Filed Apr 15, 2010 22:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-10-007016 · edgar.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,984 Underlying: Common Stock · 100,000 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a 5 year vesting schedule. 20% of the options vested on January 18, 2002, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on January 18, 2006. The options expire on January 17, 2011. Read SEC document |
| April 13, 2010 Filed Apr 15, 2010 22:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100,000 | $46.32 | $4,631,930.00 |
DisclosureSEC source: 0001179110-10-007016 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,634,042 F1 · price: Sale prices reported for the transaction reported here range from $45.76 to $46.58. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 13, 2010 Filed Apr 15, 2010 22:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $3.70 | $369,930.00 |
DisclosureSEC source: 0001179110-10-007016 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,734,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2010 Filed Mar 11, 2010 01:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-10-004952 · edgar.xml · derivative · entry 5 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 665,984 Underlying: Common Stock · 100,000 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a 5 year vesting schedule. 20% of the options vested on January 18, 2002, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on January 18, 2006. The options expire on January 17, 2011. Read SEC document |
| March 09, 2010 Filed Mar 11, 2010 01:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100,000 | $47.44 | $4,743,710.00 |
DisclosureSEC source: 0001179110-10-004952 · edgar.xml · nonDerivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,634,042 F3 · price: Sale prices reported for the transaction reported here range from $46.80 to $47.68. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 09, 2010 Filed Mar 11, 2010 01:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $3.70 | $369,930.00 |
DisclosureSEC source: 0001179110-10-004952 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,734,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2010 Filed Mar 11, 2010 01:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 32,676 | $47.01 | $1,536,098.76 |
DisclosureSEC source: 0001179110-10-004952 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,634,042 Read SEC document |
| March 08, 2010 Filed Mar 11, 2010 01:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-004952 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,666,718 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 8, 2010. Read SEC document |
| February 09, 2010 Filed Feb 12, 2010 00:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-10-002617 · edgar.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765,984 Underlying: Common Stock · 100,000 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a 5 year vesting schedule. 20% of the options vested on January 18, 2002, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on January 18, 2006. The options expire on January 17, 2011. Read SEC document |
| February 09, 2010 Filed Feb 12, 2010 00:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100,000 | $46.37 | $4,637,340.00 |
DisclosureSEC source: 0001179110-10-002617 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,596,718 F1 · price: Sale prices reported for the transaction reported here range from $46.09 to $47.00. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 09, 2010 Filed Feb 12, 2010 00:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $3.70 | $369,930.00 |
DisclosureSEC source: 0001179110-10-002617 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,696,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2010 Filed Feb 2, 2010 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 318,000 | $0.00 Strike: $47.51 | $0.00 |
DisclosureSEC source: 0001179110-10-001748 · edgar.xml · derivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,000 Underlying: Common Stock · 318,000 shares Expires 2020-01-28 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 28, 2011 the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 28, 2015. Read SEC document |
| January 12, 2010 Filed Jan 14, 2010 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 66,992 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-10-001086 · edgar.xml · derivative · entry 5 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865,984 Underlying: Common Stock · 66,992 shares Expires 2011-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options had a 5 year vesting schedule. 20% of the options vested on January 18, 2002, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on January 18, 2006. The options expire on January 17, 2011. Read SEC document |
| January 12, 2010 Filed Jan 14, 2010 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 33,008 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-10-001086 · edgar.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,008 shares Expires 2010-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a 5 year vesting schedule. 20% of the options vested on April 5, 2001, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on April 5, 2005. The options expire on April 5, 2010. Read SEC document |
| January 12, 2010 Filed Jan 14, 2010 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100,000 | $44.80 | $4,479,970.00 |
DisclosureSEC source: 0001179110-10-001086 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,596,718 F1 · price: Sale prices reported for the transaction reported here range from $44.54 to $45.02. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 12, 2010 Filed Jan 14, 2010 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 66,992 | $3.70 | $247,823.51 |
DisclosureSEC source: 0001179110-10-001086 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,696,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2010 Filed Jan 14, 2010 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 33,008 | $3.70 | $122,235.23 |
DisclosureSEC source: 0001179110-10-001086 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,629,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2009 Filed Dec 10, 2009 23:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-09-016751 · edgar.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,008 Underlying: Common Stock · 100,000 shares Expires 2010-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a 5 year vesting schedule. 20% of the options vested on April 5, 2001, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on April 5, 2005. The options expire on April 5, 2010. Read SEC document |
| December 08, 2009 Filed Dec 10, 2009 23:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100,000 | $46.16 | $4,616,300.00 |
DisclosureSEC source: 0001179110-09-016751 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,596,718 F1 · price: Sale prices reported for the transaction reported here range from $45.95 to $46.45. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 08, 2009 Filed Dec 10, 2009 23:05 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $3.70 | $370,320.00 |
DisclosureSEC source: 0001179110-09-016751 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,696,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2009 Filed Nov 13, 2009 01:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-09-015406 · edgar.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,008 Underlying: Common Stock · 100,000 shares Expires 2010-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options had a 5 year vesting schedule. 20% of the options vested on April 5, 2001, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on April 5, 2005. The options expire on April 5, 2010. Read SEC document |
| November 10, 2009 Filed Nov 13, 2009 01:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,500 | $47.12 | $117,790.75 |
DisclosureSEC source: 0001179110-09-015406 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,596,718 F2 · price: Sale prices reported for the transaction reported here range from $47.10 to $47.1325. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 10, 2009 Filed Nov 13, 2009 01:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 97,500 | $46.65 | $4,548,823.50 |
DisclosureSEC source: 0001179110-09-015406 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,599,218 F1 · price: Sale prices reported for the transaction reported here range from $46.10 to $47.06. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 10, 2009 Filed Nov 13, 2009 01:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $3.70 | $370,320.00 |
DisclosureSEC source: 0001179110-09-015406 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,696,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2009 Filed Oct 15, 2009 00:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-09-014530 · edgar.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,008 Underlying: Common Stock · 100,000 shares Expires 2010-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a 5 year vesting schedule. 20% of the options vested on April 5, 2001, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on April 5, 2005. The options expire on April 5, 2010. Read SEC document |
| October 13, 2009 Filed Oct 15, 2009 00:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100,000 | $45.40 | $4,540,070.00 |
DisclosureSEC source: 0001179110-09-014530 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,596,718 F1 · price: Sale prices reported for the transaction reported here range from $45.15 to $45.61. Full information regarding the number of shares purchased or sold at each price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 13, 2009 Filed Oct 15, 2009 00:20 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $3.70 | $370,320.00 |
DisclosureSEC source: 0001179110-09-014530 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,696,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2009 Filed Sep 9, 2009 23:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-09-013053 · edgar.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,008 Underlying: Common Stock · 100,000 shares Expires 2010-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a 5 year vesting schedule. 20% of the options vested on April 5, 2001, the first anniversary of the date of the grant. The balance vested 5% every three months thereafter until fully vested on April 5, 2005. The options expire on April 5, 2010. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.